Enclomiphene vs Thyroid (Levothyroxine / Liothyronine T3/T4)

Mechanism

Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.

Standard Dosing

Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.

Timing

Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.

Cycle Duration

Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.

Side Effects

• Headache
• Hot flashes
• Nausea (less common than racemic clomiphene)
• Elevated estradiol (from increased testosterone substrate for aromatase)
• Rare visual disturbances (significantly less than racemic clomiphene)

Contraindications

• Primary hypogonadism (elevated gonadotropins, testicular failure)
• Severe hepatic impairment
• Known hypersensitivity to clomiphene isomers
• Pituitary tumors
• Vision changes or thrombotic history warrant caution

Best Stacking Partners

Mechanism

Levothyroxine (T4) is a prohormone converted to the active triiodothyronine (T3) by type 1 and type 2 deiodinase enzymes (DIO1/DIO2) in peripheral tissues. T3 binds nuclear thyroid hormone receptors (TRa and TRb), forming heterodimers with retinoid X receptors (RXR) that bind thyroid response elements (TREs) in DNA, directly modulating transcription of genes controlling basal metabolic rate, thermogenesis, mitochondrial biogenesis (via PGC-1a), cardiac output, and neuronal development. T3 also exerts rapid non-genomic effects on mitochondrial respiration, ion channels, and cell membrane transport.

Standard Dosing

Research indicates Levothyroxine (T4): 25-200 mcg daily based on TSH and free T4 levels. Liothyronine (T3): 5-25 mcg daily, often split into 2-3 doses. Combination T4/T3 ratio typically 4:1 to 3:1 when using both.

Timing

Levothyroxine: Take on empty stomach, 30-60 minutes before breakfast or at bedtime (3+ hours after last meal). Separate from calcium, iron, and antacids by 4 hours. Liothyronine: Split into 2-3 daily doses due to short half-life (2.5 hours for T3 vs. 6-7 days for T4).

Cycle Duration

Ongoing for diagnosed hypothyroidism. Optimization protocols may be shorter-term (3-6 months) with reassessment.

Side Effects

• Tachycardia and palpitations (overdose or too-rapid titration)
• Anxiety and insomnia (particularly with T3)
• Tremor
• Weight loss (excessive dosing)
• Hair loss (temporary during initiation or dose changes)
• Heat intolerance and sweating
• Bone density loss at suppressive doses (TSH <0.1)

Contraindications

• Untreated adrenal insufficiency (correct cortisol before thyroid replacement)
• Acute myocardial infarction
• Thyrotoxicosis
• Known hypersensitivity to levothyroxine or liothyronine

Best Stacking Partners